BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BioCentury | Sep 28, 2018
Company News

China Medical gets Asian rights to Vaximm's immunotherapy portfolio

China Medical System Holdings Ltd. (HKSE:867) gained an exclusive license from Vaximm AG (Basel, Switzerland) to develop and commercialize Vaximm's oral cancer immunotherapy pipeline in China, Hong Kong, Macau, Taiwan and other Asian countries. The...
BioCentury | Jun 1, 2018
Clinical News

Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

Vaximm AG (Basel, Switzerland) reported final data from 14 patients with recurrent glioblastoma in a Phase I trial showing that oral VXM01 on days 1, 3, 5 and 7 led to one durable objective response...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BioCentury | Oct 20, 2017
Product R&D

Fighting cancer by mouth

With its first compound through Phase I, Vaximm AG has started to unveil the data and technology behind its preclinical pipeline of oral cancer vaccines. Using an attenuated Salmonella strain, the company is building a...
BioCentury | Jun 1, 2017
Company News

Vaximm combining VXM01 and Bavencio

Vaximm AG (Basel, Switzerland) will conduct two open-label trials evaluating its VXM01 in combination with PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK). Vaximm declined to provide a start date for the trials, which will...
BioCentury | Sep 9, 2016
Company News

Management tracks

Oncology company Vaximm AG (Basel, Switzerland) named Matthias Schroff CEO. He was CEO at Mologen AG (Xetra:MGN). Sanofi (Euronext:SAN; NYSE:SNY) named Frank Nestle CSO for North America and global head of immunology and inflammation research....
BioCentury | Jul 25, 2016
Clinical News

VXM01: Phase I started

Vaximm began an open-label, German Phase I trial to evaluate 4 vaccinations of 1 and 10 million colony forming units (CFUs) of oral VXM01 given 4-5 weeks before surgery in 6 patients who received >=1...
BioCentury | Jun 27, 2016
Clinical News

VXM01: Phase I data

Data from 16 evaluable patients with advanced pancreatic cancer in a dose-escalation, placebo-controlled Phase I trial showed that low- and high-dose VXM01 led to increases in vaccine-specific T cell responses in 66.7% (n=12) and 75%...
BioCentury | May 16, 2016
Clinical News

VXM01: Phase IIa started

Vaximm began a German Phase IIa trial to evaluate oral VXM01 plus standard chemotherapy in 24 patients whose disease has progressed after 1-2 prior therapies. Patients will receive 4 vaccinations of VXM01 the first week...
Items per page:
1 - 10 of 15
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BioCentury | Sep 28, 2018
Company News

China Medical gets Asian rights to Vaximm's immunotherapy portfolio

China Medical System Holdings Ltd. (HKSE:867) gained an exclusive license from Vaximm AG (Basel, Switzerland) to develop and commercialize Vaximm's oral cancer immunotherapy pipeline in China, Hong Kong, Macau, Taiwan and other Asian countries. The...
BioCentury | Jun 1, 2018
Clinical News

Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

Vaximm AG (Basel, Switzerland) reported final data from 14 patients with recurrent glioblastoma in a Phase I trial showing that oral VXM01 on days 1, 3, 5 and 7 led to one durable objective response...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BioCentury | Oct 20, 2017
Product R&D

Fighting cancer by mouth

With its first compound through Phase I, Vaximm AG has started to unveil the data and technology behind its preclinical pipeline of oral cancer vaccines. Using an attenuated Salmonella strain, the company is building a...
BioCentury | Jun 1, 2017
Company News

Vaximm combining VXM01 and Bavencio

Vaximm AG (Basel, Switzerland) will conduct two open-label trials evaluating its VXM01 in combination with PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK). Vaximm declined to provide a start date for the trials, which will...
BioCentury | Sep 9, 2016
Company News

Management tracks

Oncology company Vaximm AG (Basel, Switzerland) named Matthias Schroff CEO. He was CEO at Mologen AG (Xetra:MGN). Sanofi (Euronext:SAN; NYSE:SNY) named Frank Nestle CSO for North America and global head of immunology and inflammation research....
BioCentury | Jul 25, 2016
Clinical News

VXM01: Phase I started

Vaximm began an open-label, German Phase I trial to evaluate 4 vaccinations of 1 and 10 million colony forming units (CFUs) of oral VXM01 given 4-5 weeks before surgery in 6 patients who received >=1...
BioCentury | Jun 27, 2016
Clinical News

VXM01: Phase I data

Data from 16 evaluable patients with advanced pancreatic cancer in a dose-escalation, placebo-controlled Phase I trial showed that low- and high-dose VXM01 led to increases in vaccine-specific T cell responses in 66.7% (n=12) and 75%...
BioCentury | May 16, 2016
Clinical News

VXM01: Phase IIa started

Vaximm began a German Phase IIa trial to evaluate oral VXM01 plus standard chemotherapy in 24 patients whose disease has progressed after 1-2 prior therapies. Patients will receive 4 vaccinations of VXM01 the first week...
Items per page:
1 - 10 of 15